Taylor & Francis Group
Browse
ionc_a_1670862_sm7721.doc (28.5 kB)

Combination chemotherapy with temozolomide, lomustine, vincristine and interferon-alpha (TOL-IFN) plus vemurafenib or TOL-IFN as first-line treatment for patients with advanced melanoma

Download (28.5 kB)
journal contribution
posted on 2019-09-28, 12:37 authored by Kalle E. Mattila, Pia Vihinen, Susan Ramadan, Tanja Skyttä, Leena Tiainen, Meri-Sisko Vuoristo, Kristiina Tyynelä-Korhonen, Jussi Koivunen, Laura Kohtamäki, Siru Mäkelä, Micaela Hernberg
Combination chemotherapy with temozolomide, lomustine, vincristine and interferon-alpha (TOL-IFN) plus vemurafenib or TOL-IFN as first-line treatment for patients with advanced melanoma

Funding

Vemurafenib was provided by ROCHE before it was reimbursable in Finland in 2016 and Finnish Melanoma Group has received funding from ROCHE. Mattila reports grants from Turku University Hospital Foundation, Tuulikki Edessalo Foundation and Finnish Melanoma Group. This study was also supported by F. Hoffmann-La Roche.

History

Usage metrics

    Acta Oncologica

    Categories

    Keywords

    first-line treatmentvemurafenibinterferon-alphavincristineTOL-IFNmelanoma Combination chemotherapytemozolomidelomustine

    Licence

    CC BY 4.0

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC